CAMBRIDGE, Mass.--(BUSINESS WIRE)--Synlogic announced today that its President and Chief Executive Officer, Jose Carlos Gutierrez-Ramos, Ph.D., will speak at the 2017 Wedbush PacGrow Healthcare Conference at 3:05 p.m. ET on Wednesday, August 16th, 2017, in New York City.
Synlogic is advancing a novel new class of living medicines using the company’s proprietary discovery and development platform. The company’s Synthetic Biotic™ medicines are designed to perform critical metabolic functions or deliver therapeutic factors to compensate for what is missing or damaged due to disease. Synthetic Biotic medicines have the potential to be deployed against a wide array of diseases ranging from rare metabolic disorders to inflammatory bowel disease to cancer.
About Synthetic Biotic™ Medicines:
Synlogic’s innovative new
class of Synthetic Biotic medicines leverages the tools and principles
of synthetic biology to genetically reengineer beneficial, probiotic
microbes to perform critical functions or deliver therapeutic factors to
compensate for what is missing or damaged due to disease. The company’s
two lead programs target diseases known as inborn errors of metabolism.
Patients with these rare metabolic diseases are born with a faulty gene,
which inhibits the body’s ability to break down commonly occurring
by-products of digestion that then accumulate to toxic levels with
serious health consequences. When delivered orally, Synthetic Biotic
medicines are designed to act from the gut to compensate for the
dysfunctional metabolic pathway and have a systemic effect, clearing
toxic metabolites associated with specific metabolic diseases. Synthetic
Biotic medicines have the potential to significantly improve the quality
of life for affected patients.
About Synlogic™
Synlogic™ is pioneering the development of a
novel class of living treatments, Synthetic Biotic medicines, based on
its proprietary drug discovery and development platform. Synlogic’s
initial pipeline includes Synthetic Biotic medicines for the treatment
of rare genetic diseases, such as Urea Cycle Disorder (UCD) and
Phenylketonuria (PKU). In addition, the company is leveraging the broad
potential of its platform to create Synthetic Biotic medicines for the
treatment of more common diseases, including liver disease, inflammatory
and immune disorders, and cancer. Synlogic is collaborating with AbbVie
to develop Synthetic Biotic-based treatments for inflammatory bowel
disease (IBD). For more information, please visit www.synlogictx.com.
Forward Looking Statements:
This press release contains
“forward-looking statements” that involve substantial risks and
uncertainties for purposes of the safe harbor provided by the Private
Securities Litigation Reform Act of 1995. All statements, other than
statements of historical facts, included in this press release regarding
strategy, future operations, future financial position, future revenue,
projected expenses, prospects, plans and objectives of management are
forward-looking statements. In addition, when or if used in this press
release, the words “may,” “could,” “should,” “anticipate,” “believe,”
“estimate,” “expect,” “intend,” “plan,” “predict” and similar
expressions and their variants, as they relate to Synlogic may identify
forward-looking statements. Examples of forward-looking statements,
include, but are not limited to, statements regarding the potential of
Synlogic’s platform to develop therapeutics to address a wide range of
diseases, including IBD, and the continued preclinical development of
Synthetic Biotic-based treatments pursuant to the AbbVie collaboration.
Actual results could differ materially from those contained in any
forward-looking statement as a result of various factors, including, the
uncertainties inherent in the preclinical development process, the
ability of Synlogic to protect its intellectual property rights and
legislative, regulatory, political and economic developments.